Neurocrine (NBIX), which has developed a drug for congenital adrenal hyperplasia, has launched a new interactive website to ...

According to Neurocrine, the site is aimed at teenagers and adults with CAH, as well as their caregivers, the parents of ...

Cencora's (COR) second-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions ...

Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amputees who try to join the U.S. armed forces are rejected, no matter how capable they are. Hannah Cvancara wants to change ...

Cardinal Health (CAH) ended the recent trading session at $103.37, demonstrating a +0.53% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.2 ...

Neurocrine Biosciences’ newly-debuted campaign acknowledges the frustration that congenital adrenal hyperplasia (CAH) ...

Stock futures inched higher in the early trading hours of Monday, ahead of earnings reports from major tech companies such as ...

Buying $100 In CAH: If an investor had bought $100 of CAH stock 5 years ago, it would be worth $215.89 today based on a price ...

Super Micro Computer SMCI is scheduled to report its third-quarter fiscal 2024 results on Apr 30. The company has been ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks, especially industry leaders that offer a ...

Drug distributor backs fiscal 2024 profit guidance despite end of contract that generated 16% of its revenue last year.